This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by WILKINS, R. W. Articles by HOLLANDER, W. Search for Related Content PubMed PubMed Citation Articles by WILKINS, R. W. Articles by HOLLANDER, W.

(Circulation. 1957;16:256.)
© 1957 American Heart Association, Inc.

---

Serotonin and Antiserotonins

II. Clinical Studies, Especially in Essential Hypertension with the Benzyl Analog of Serotonin (BAS)

ROBERT W. WILKINS M.D.¹ WILLIAM HOLLANDER M.D.¹

¹ From the Robert Dawson Evans Memorial, Massachusetts Memorial Hospitals, and the Department of Medicine, Boston University School of Medicine, Boston, Mass.

Serotonin, a smooth-muscle constrictor, has been suggested as possibly important in the pathogenesis of arterial hypertension. The benzyl analog of serotonin (BAS) was developed as an antimetabolite of serotonin, and has certain demonstrable antiserotonin effects in man. Orally it has moderate antihypertensive and other clinical effects resembling those of reserpine, which also has a definite antiserotonin action. However, there is question whether the clinical effects of oral BAS or of reserpine in hypertension are due to "antiserotonin" or other pharmacologic actions. BAS is clinically useful in the therapy of some patients with essential hypertension.